Market Research Future published a half-cooked research report on the Global Herpes
Zoster Market.
Market Highlights:
Herpes zoster (shingles) spreads from people suffering from chicken-pox. The mode of
transmission is through metabolic process droplets, skin lesions, by direct contact or
through aerosols. Currently, there are only two vaccines licensed and available in the US for
shingles namely Zostavax (zoster vaccine live) and Shingrix (recombinant zoster vaccine).
Both these vaccines are safe and effective and has potential side effects.
Generally, the diagnosis of this condition is through laboratory testing. Additionally, the first
line of treatment is through medication which include oral medicines (Antihistamines),
topical (numbing creams, gels, or patches), and vaccines. Typically, the vaccines are
administered to the geriatric population as they are at a higher risk to contract this disease.
The herpes zoster market is expected to witness tremendous growth owing to rising
incidence of herpes zoster coupled with rising geriatric population are factors contributing
towards the growth of the market. Moreover, the risk of developing herpes zoster increases
with age. However, challenges such as the limited number of pipeline agents for the
treatment of herpes zoster despite the growing incidence of the infection worldwide is likely
to curb the market growth during the forecast period.
Global Herpes Zoster Market Key Players:
Astellas Pharma Inc. (Japan), Foamix Pharmaceuticals (Israel), Geneone Life Science (South
Korea), GlaxoSmithKline plc (UK), Merck & Co. Inc. (US), NAL Pharma (Hong Kong),
Novartis AG (Switzerland), F. Hoffmann-La Roche Ltd. (Switzerland), TSRL, Inc. and others
Segmentation:
The global herpes zoster market is segmented into Diagnosis, application, end-users. The
herpes zoster market, by Diagnosis, the market is segmented into laboratory testing and
others. The laboratory testing segment is further categorized into immunofluorescent
microscopy, real-time Polymerase Chain Reaction (PCR), serological testing. The treatment
and prevention segment for the global herpes zoster market is divided into antiviral
medications, narcotic medications, anti-inflammatory medications, antihistamines,
anticonvulsants, capsaicin, numbing creams, gels, or patches, vaccines, and others. The
route of administration segment for the global herpes zoster market is divided into oral,
topical, and others. The end-user segment for the global herpes zoster market is divided
into hospitals & clinics, diagnostic centers, research & academic institutes, home care
settings, and others.
Regional Analysis:
The Americas is the largest in the market owing to the increasing government support for